Both treatment resistance and toxicities remain risks following CAR T-cell therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL). Utilizing the ZUMA-7 dataset, the largest available for CAR T-cell therapy in second-line LBCL, Filosto, Vardhanabhuti et al. report pharmacokinetics, serum pharmacodynamics, and product and apheresis attributes associated with efficacy or high-grade toxicity among patients treated with axicabtagene ciloleucel (axi-cel), including a naive-like (CCR7+CD45RA+) T-cell phenotype associated with better patient outcomes. These findings have implications on clinical practice, including supporting earlier referral of patients with LBCL for CAR T-cell therapy and informing development of next-generation CAR T-cell products.

See article, p. 21.

Immunomodulatory imide drugs (IMiD) are a staple of myeloma therapy; however, their efficacy is limited by development of resistance. In this issue, Welsh, Barwick et al uncover mechanisms of resistance and a combinatorial therapy approach. IMiDs act by targeting IKZF1 and IKZF3 for degradation. IKZF1/3 transcription factors recruit...

You do not currently have access to this content.